142 related articles for article (PubMed ID: 18071308)
1. The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
Odgerel T; Kikuchi J; Wada T; Shimizu R; Futaki K; Kano Y; Furukawa Y
Oncogene; 2008 May; 27(22):3102-10. PubMed ID: 18071308
[TBL] [Abstract][Full Text] [Related]
2. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Furukawa Y; Vu HA; Akutsu M; Odgerel T; Izumi T; Tsunoda S; Matsuo Y; Kirito K; Sato Y; Mano H; Kano Y
Leukemia; 2007 May; 21(5):1005-14. PubMed ID: 17330105
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
4. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
Yoshida A; Ookura M; Zokumasu K; Ueda T
Biochem Pharmacol; 2014 Jul; 90(1):16-24. PubMed ID: 24735609
[TBL] [Abstract][Full Text] [Related]
5. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
[TBL] [Abstract][Full Text] [Related]
6. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
[TBL] [Abstract][Full Text] [Related]
8. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
Ahmad R; Liu S; Weisberg E; Nelson E; Galinsky I; Meyer C; Kufe D; Kharbanda S; Stone R
Mol Cancer Res; 2010 Jul; 8(7):986-93. PubMed ID: 20571062
[TBL] [Abstract][Full Text] [Related]
9. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
[TBL] [Abstract][Full Text] [Related]
10. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
Zeng Z; Samudio IJ; Zhang W; Estrov Z; Pelicano H; Harris D; Frolova O; Hail N; Chen W; Kornblau SM; Huang P; Lu Y; Mills GB; Andreeff M; Konopleva M
Cancer Res; 2006 Apr; 66(7):3737-46. PubMed ID: 16585200
[TBL] [Abstract][Full Text] [Related]
12. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
13. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
[TBL] [Abstract][Full Text] [Related]
14. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
15. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
16. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Waldeck S; Rassner M; Keye P; Follo M; Herchenbach D; Endres C; Charlet A; Andrieux G; Salzer U; Boerries M; Duyster J; von Bubnoff N
Mol Oncol; 2020 Apr; 14(4):779-794. PubMed ID: 31955503
[TBL] [Abstract][Full Text] [Related]
17. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Weisberg E; Choi HG; Barrett R; Zhou W; Zhang J; Ray A; Nelson EA; Jiang J; Moreno D; Stone R; Galinsky I; Fox E; Adamia S; Kung AL; Gray NS; Griffin JD
Mol Cancer Ther; 2010 Sep; 9(9):2468-77. PubMed ID: 20807780
[TBL] [Abstract][Full Text] [Related]
19. H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.
Woolley JF; Naughton R; Stanicka J; Gough DR; Bhatt L; Dickinson BC; Chang CJ; Cotter TG
PLoS One; 2012; 7(7):e34050. PubMed ID: 22807997
[TBL] [Abstract][Full Text] [Related]
20. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Nishioka C; Ikezoe T; Yang J; Takeshita A; Taniguchi A; Komatsu N; Togitani K; Koeffler HP; Yokoyama A
Leuk Res; 2008 Jun; 32(6):865-72. PubMed ID: 17983653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
